Incidence of anterior segment neovascularization during intravitreal treatment for
            macular edema secondary to central retinal vein occlusion

Lucatto, Luiz Filipe Adami; Magalhães-Junior, Octaviano; Prazeres, Juliana; Ferreira, Adriano Menis; Oliveira, Ramon Antunes de; Moraes, Nilva S.; Hirai, Flavio E.; Maia, Mauricio

doi:10.5935/0004-2749.20170024

Cited by 5 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 11 eligible studies, 5 RCTs (12 publications) were separately published at different follow-up periods. Three RCTs were excluded from quantitative synthesis: a study conducted by Khan and colleagues [17] comparing efficacy of 1.25 mg of IVB starting at month 0 (immediate) and month 4 (deferred), a study conducted by Moradian et al [18] which followed patients for only 3 months, and a study by Lucatto et al [19] that reported outcomes as graphs without specific values.…”

Section: Discussionmentioning

confidence: 99%

“…The studies of Khan et al [17] and Epstein et al [32,33] were suggested that prompt IVB treatment had greater efficacy and needed lesser numbers of the drug injection as well as rescue laser treatment compared to delayed treatment. A small study (n = 35) [19] examining functional and anatomic outcomes as secondary end point found that improvement of BCVA in IVB group was significantly better than intravitreal triamcinolone acetate (IVTA) and sham groups only at month 1, while there was no statistically significant difference in CMT reduction throughout the study period.…”

Section: Efficacy Outcomesmentioning

confidence: 98%

“…Retinal thickness at baseline had to be at least 250 or 300 μm in order to be eligible for participating in the studies. The optical coherence tomography (OCT) machines (manufacturers) used to measure CMT were varied across studies: Cirrus HD-OCT (Carl Zeiss Meditec Inc., Dublin, CA, USA) [13,17,31,32], Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany) [13,19], Stratus OCT (Carl Zeiss Meditec Inc., Dublin, CA, USA and Carl Zeiss Meditec, Jena, Germany) [18,20,23,25,28,30], and 3D-OCT 1000 (Topcon Corporation, Tokyo, Japan) [20]. Using different OCT machines might result in slight difference in measured CMT values.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Approximately 73% of studies reported mean time from RVO diagnosis and they included only patients who were diagnosed with RVO within 12 months prior to enrollment. Most studies used ETDRS chart which was commonly used in clinical research studies except three studies [17][18][19] that measured BCVA by using the Snellen chart. In each trial, patients' baseline characteristics, including age, baseline BCVA, and baseline CMT, were similar between the comparison groups.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…In most trials, patients received the monthly injection of the drugs for the first 5 or 6 months [13,19,[21][22][23][24][25][26][27][28][29][30] (for 3 months in ROCC [20]), then followed by monthly pro re nata (PRN or as needed) regimen in the extension phase. MARVEL [31] applied the monthly PRN regimen throughout the study period.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis

Sangroongruangsri

Ratanapakorn

et al. 2018

Expert Review of Clinical Pharmacology

View full text Add to dashboard Buy / Rent full text

Anti-vascular endothelial growth factor (VEGF) therapy has become the most commonly used treatment for macular edema secondary to retinal vein occlusion (RVO). Although its superior efficacy as compared to other interventions has been proven, there is a lack of evidence for relative efficacy among anti-VEGF drugs. Areas covered: This work systematically reviewed and compared the efficacy of intravitreal bevacizumab, ranibizumab, and aflibercept for treating macular edema due to RVO. PubMed, EMBASE, and the Cochrane Library were searched from their inception until October 2017. Eleven randomized controlled trials (18 articles; 1830 adult patients) were identified. The proportion of patients who gained at least 15 letters in best-corrected visual acuity (BCVA), mean change from baseline in BCVA, and mean change from baseline in central macular thickness (CMT) were reported and these efficacy outcomes at 6 months were analyzed in network meta-analysis. Expert commentary: Apparently, bevacizumab, ranibizumab, and aflibercept were significantly superior to sham injection in terms of BCVA improvement and CMT reduction and had good safety profiles. However, there were no statistically significant differences in any outcomes among anti-VEGF drugs. In selecting an anti-VEGF drug for individual patients, other factors including affordability, drug availability, and patient characteristics should be considered.

show abstract

Section: Discussionmentioning

confidence: 99%